Key facts
- This page summarizes GILEAD SCIENCES, INC.'s Form 4 filing for Allovir, Inc. (KLRS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 28 Jun 2023, 17:17.
GILEAD SCIENCES, INC. - 27 Jun 2023 Form 4 Insider Report for Allovir, Inc. (KLRS)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- KLRS
- Reported as of
- 27 Jun 2023
- Net transaction value
- +$10,990,762
- SEC form
- 4
- Accepted by SEC
- 28 Jun 2023, 17:17:16 UTC
- Prior SEC filing
- 05 Aug 2022
- Next SEC filing
- 30 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- Gilead Sciences, Inc.
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
GILEAD SCIENCES, INC. filed Form 4 for Allovir, Inc. (KLRS) on 28 Jun 2023.
Change
- Previous filing in this sequence was filed on 05 Aug 2022.
- Current net transaction value: +$10,990,762.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ALVR
transaction
Common Stock
Purchase
- Transaction value
- $10,990,762
- Shares
- +2,930,870
- Change %
- +21%
- Price
- $3.75
- Shares after
- 16,635,286
- Date
- 27 Jun 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.